Sepsis Diagnostics Market
完整報告名稱與涵蓋範圍
Sepsis Diagnostics Market by Technology (Blood Culture, PCR, Immunoassay), Product (Culture, Assay, Instruments), Sample (Serum, blood), Test Type (Lab, POC), Pathogen (Bacterial), End User (Hospital, Pathology & Reference Labs) - Global Forecast to 2031
報告摘要
The sepsis diagnostics market is projected to reach USD 1.22 billion by 2031, up from USD 0.83 billion in 2026, at a CAGR of 7.9%. The global sepsis diagnostics market is expected to grow steadily over the forecast period, driven by the rising burden of sepsis and bloodstream infections, increasing ICU admissions, growing demand for rapid pathogen identification, and rising adoption of molecular diagnostics, automated microbiology platforms, immunoassays, and biomarker-based testing. Market growth is further supported by the increasing focus on antimicrobial stewardship programs, the need to reduce diagnostic turnaround time, and the adoption of automated diagnostic workflows in hospital and reference laboratories. However, the high cost of advanced molecular diagnostic platforms, limited reimbursement for novel diagnostic technologies, the clinical complexity of sepsis presentation, workflow integration challenges, and a shortage of trained laboratory personnel are expected to restrain market growth to some extent.
“Assays & reagent kits accounted for the largest share of the sepsis diagnostics market, by product, in 2025.”
By product, the sepsis diagnostics market is segmented into blood culture media, assays & reagent kits, instruments, and software. In 2025, assays & reagent kits accounted for the largest market share, driven by their recurring use in blood culture testing, immunoassays, molecular diagnostics, antimicrobial susceptibility testing, and biomarker-based sepsis assessment. Rising demand for pathogen detection kits, PCR-based reagents, syndromic testing panels, inflammatory biomarker assays, and sepsis-related consumables continues to support this segment's dominance. Additionally, the growing adoption of automated and molecular testing platforms across hospitals and reference laboratories is further strengthening demand for assays and reagent kits.
“Blood culture/microbiology testing accounted for the largest share of the sepsis diagnostics market, by technology, in 2025.”
By technology, the global sepsis diagnostics market is segmented into blood culture/microbiology testing, immunoassays, molecular diagnostics, flow cytometry, mass spectrometry, and clinical chemistry & blood gas analysis. In 2025, blood culture/microbiology testing accounted for the largest share, reflecting its established role as the standard diagnostic approach for detecting bloodstream infections and supporting antimicrobial susceptibility testing. These technologies are widely used in hospital microbiology laboratories for pathogen detection, organism identification, and therapy guidance. However, molecular diagnostics is expected to grow faster over the forecast period, supported by increasing adoption of PCR/RT-PCR, multiplex PCR panels, microarrays, FISH/PNA-FISH, DNA sequencing, NGS, LAMP, and TMA-based methods for rapid pathogen and resistance marker detection.
“The Asia Pacific region is projected to grow at the highest CAGR in the sepsis diagnostics market from 2026 to 2031.”
The sepsis diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, the Asia Pacific region is projected to have the highest CAGR, driven by the rising burden of infectious diseases and bloodstream infections, expanding hospital and ICU infrastructure, rising healthcare expenditure, and growing adoption of automated microbiology and molecular diagnostic platforms. Growth is further supported by improving laboratory capacity, greater awareness of sepsis management, rising demand for rapid diagnostics, and large patient populations across China, Japan, India, South Korea, Australia, and Southeast Asia.
List of Companies Profiled in the Report
• Biomérieux
• Becton Dickinson and Company
• Danaher Corporation
• Diasorin S.P.A (Luminex)
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific, Inc
• Bruker Corporation
• Abbott Laboratories
• Sysmex Corporation
• Siemens Healthineers
• Qiagen
• Quidelortho Corporation
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Research Coverage
This research report categorizes the sepsis diagnostics market by product, technology, method, pathogen type, test type, sample type, complexity, clinical utility/management pathway, end user, and region. The scope of the report covers detailed information on the major factors influencing the market, including drivers, restraints, opportunities, and challenges. It includes a detailed analysis of key industry players, providing insights into their business overview, product portfolio, key strategies such as product launches, regulatory approvals, collaborations, partnerships, acquisitions, and expansions, as well as recent developments associated with the sepsis diagnostics market. This report also covers a competitive analysis of leading players and emerging companies in the sepsis diagnostics ecosystem.
Key Benefits of Buying the Report
The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall sepsis diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. The report will enable stakeholders to understand the market pulse and provide information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following points:
• Analysis of key drivers, including the high incidence of sepsis and bloodstream infections, growing adoption of rapid molecular and syndromic diagnostics, increasing focus on antimicrobial stewardship, and expansion of biomarker-based testing; restraints, including the high cost of advanced molecular diagnostic platforms and limited reimbursement for novel diagnostic technologies; opportunities, including AI-enabled sepsis diagnosis, clinical decision support, next-generation host-response biomarkers, rapid POC testing, and decentralized testing; and challenges, including clinical complexity, heterogeneous sepsis presentation, integration into hospital workflows, and a shortage of trained laboratory personnel
• Product Development/Innovation: Detailed insights into newly launched and emerging sepsis diagnostics products, including automated blood culture systems, molecular diagnostic panels, syndromic testing platforms, immunoassays, biomarker-based tests, mass spectrometry-based microbial identification platforms, antimicrobial susceptibility testing solutions, and AI-enabled clinical decision support tools
• Market Development: Comprehensive information about lucrative markets — the report analyzes the sepsis diagnostics market across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with detailed assessment of major country-level opportunities and adoption trends
• Market Diversification: Comprehensive information on product portfolios, technological developments, regulatory approvals, collaborations, partnerships, acquisitions, geographic expansions, and investments in the sepsis diagnostics market
Competitive Assessment: In-depth assessment of market shares, growth strategies, technological capabilities, diagnostic platforms, service offerings, and competitive positioning of leading players, including bioMérieux SA, Becton, Dickinson and Company, Danaher Corporation, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Bruker Corporation, and DiaSorin S.p.A., among others
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.3 STUDY SCOPE 47
1.3.1 MARKETS COVERED & REGIONAL SCOPE 47
1.3.2 INCLUSIONS & EXCLUSIONS 48
1.3.3 YEARS CONSIDERED 49
1.3.4 CURRENCY CONSIDERED 49
1.4 STAKEHOLDERS 49
1.5 SUMMARY OF CHANGES 50
2 EXECUTIVE SUMMARY 51
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 51
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 52
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 53
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 54
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 55
3 PREMIUM INSIGHTS 56
3.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW 56
3.2 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031 57
3.3 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031 57
3.4 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2026 VS. 2031 58
3.5 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2026 VS. 2031 58
3.6 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2026 VS. 2031 59
3.7 SEPSIS DIAGNOSTICS MARKET, SAMPLE TYPE, 2026 VS. 2031 59
3.8 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2026 VS. 2031 60
3.9 SEPSIS DIAGNOSTICS MARKET, CLINICAL UTILITY/MANAGEMENT PATHWAY,
2026 VS. 2031 60
3.10 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031 61
3.11 SEPSIS DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61
4 MARKET OVERVIEW 62
4.1 INTRODUCTION 62
4.2 MARKET DYNAMICS 63
4.2.1 DRIVERS 63
4.2.1.1 High incidence of sepsis and bloodstream infections 63
4.2.1.2 Growing adoption of rapid molecular and syndromic diagnostics 64
4.2.1.3 Increasing focus on antimicrobial stewardship and expansion of biomarker-based testing for early sepsis detection and risk assessment 64
4.2.2 RESTRAINTS 65
4.2.2.1 High cost of advanced molecular diagnostic platforms 65
4.2.2.2 Limited reimbursement for novel sepsis diagnostic technologies 66
4.2.3 OPPORTUNITIES 66
4.2.3.1 AI-enabled sepsis diagnosis and clinical decision support 66
4.2.3.2 Development of next-generation host-response biomarkers 66
4.2.3.3 Growth of rapid POC and decentralized testing 67
4.2.4 CHALLENGES 67
4.2.4.1 Clinical complexity and heterogeneous presentation of sepsis 67
4.3 UNMET NEEDS & WHITE SPACES 68
4.3.1 UNMET NEEDS IN SEPSIS DIAGNOSTICS MARKET 68
4.3.2 WHITE SPACE OPPORTUNITIES 69
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 70
4.4.1 INTERCONNECTED MARKETS 70
4.4.2 CROSS-SECTOR OPPORTUNITIES 72
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 73
4.5.1 KEY MOVES & STRATEGIC FOCUS 73
5 INDUSTRY TRENDS 75
5.1 PORTER’S FIVE FORCES ANALYSIS 75
5.1.1 BARGAINING POWER OF SUPPLIERS 76
5.1.2 BARGAINING POWER OF BUYERS 76
5.1.3 THREAT OF NEW ENTRANTS 76
5.1.4 THREAT OF SUBSTITUTES 77
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 77
5.2 MACROECONOMIC OUTLOOK 77
5.2.1 INTRODUCTION 77
5.2.2 GDP TRENDS & FORECAST 77
5.2.3 TRENDS IN GLOBAL SEPSIS DIAGNOSTICS INDUSTRY 81
5.3 SUPPLY CHAIN ANALYSIS 81
5.4 VALUE CHAIN ANALYSIS 83
5.5 ECOSYSTEM ANALYSIS 87
5.5.1 SEPSIS DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 88
5.6 PRICING ANALYSIS 89
5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024–2026 89
5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2024–2026 90
5.7 TRADE ANALYSIS 91
5.7.1 IMPORT SCENARIO (HS CODE 3822) 92
5.7.2 EXPORT SCENARIO (HS CODE 3822) 93
5.8 KEY CONFERENCES & EVENTS, 2026–2027 93
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
5.10 INVESTMENT & FUNDING SCENARIO 95
5.11 IMPACT OF US TARIFFS—SEPSIS DIAGNOSTICS MARKET 96
5.11.1 INTRODUCTION 96
5.11.2 KEY TARIFF RATES 96
5.11.3 PRICE IMPACT ANALYSIS 97
5.11.4 IMPACT ON REGIONS 97
5.11.4.1 North America 97
5.11.4.2 Europe 98
5.11.4.3 Asia Pacific 98
5.11.5 IMPACT ON END-USE INDUSTRIES 98
5.11.5.1 Hospital and specialty clinics 98
5.11.5.2 Pathology and reference laboratories 98
5.11.5.3 Research laboratories, academic institutes, and CROs 99
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 100
6.1 KEY EMERGING TECHNOLOGIES 100
6.1.1 HOST-RESPONSE DIAGNOSTICS (TRANSCRIPTOMICS & IMMUNE PROFILING) 100
6.1.2 AI-ENABLED AND PREDICTIVE SEPSIS DIAGNOSTICS 100
6.2 COMPLEMENTARY TECHNOLOGIES 100
6.2.1 RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING (RAPID AST) 100
6.2.2 NEXT-GENERATION SEQUENCING (NGS) AND METAGENOMIC SEQUENCING 101
6.3 ADJACENT TECHNOLOGIES 101
6.3.1 CONTINUOUS PATIENT MONITORING & CLINICAL DECISION SUPPORT SYSTEMS (CDSS) 101
6.4 TECHNOLOGY/PRODUCT ROADMAP 101
6.5 PATENT ANALYSIS 103
6.5.1 LIST OF MAJOR PATENTS 104
6.6 FUTURE APPLICATIONS 105
6.7 IMPACT OF AI/GENERATIVE AI ON SEPSIS DIAGNOSTICS MARKET 106
6.7.1 INTRODUCTION 106
6.7.2 TOP USE CASES & MARKET POTENTIAL 107
6.7.3 KEY COMPANIES IMPLEMENTING AI 108
6.7.4 FUTURE OF AI 108
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 109
7.1 REGIONAL REGULATIONS & COMPLIANCE 109
7.1.1 REGULATORY ANALYSIS 109
7.1.1.1 North America 109
7.1.1.1.1 US 109
7.1.1.1.2 Canada 109
7.1.1.2 Europe 109
7.1.1.2.1 Germany 110
7.1.1.2.2 UK 111
7.1.1.2.3 France 111
7.1.1.2.4 Italy 111
7.1.1.3 Asia Pacific 112
7.1.1.3.1 China 112
7.1.1.3.2 Japan 112
7.1.1.3.3 India 112
7.1.1.3.4 Australia 113
7.1.1.4 Latin America 113
7.1.1.4.1 Brazil 114
7.1.1.4.2 Mexico 114
7.1.1.5 Middle East 114
7.1.1.5.1 Africa 114
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 115
7.2 SUSTAINABILITY INITIATIVES 116
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES 116
7.2.1.1 Eco-friendly initiatives 117
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 117
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 119
8.1 DECISION-MAKING PROCESS 119
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 120
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 120
8.2.2 BUYING CRITERIA 121
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 121
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 124
8.5 MARKET PROFITABILITY 124
8.6 REVENUE POTENTIAL 124
8.6.1 COST DYNAMICS 125
9 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT 126
9.1 INTRODUCTION 127
9.2 BLOOD CULTURE MEDIA 127
9.2.1 CONTINUED RELIANCE ON BLOOD CULTURE AS GOLD STANDARD FOR BLOODSTREAM INFECTION DIAGNOSIS SUSTAINS DEMAND 127
9.3 ASSAYS & REAGENT KITS 131
9.3.1 INCREASING ADOPTION OF RAPID MOLECULAR AND BIOMARKER-BASED TESTING DRIVES RECURRING DEMAND FOR ASSAYS AND REAGENT KITS 131
9.4 INSTRUMENTS 135
9.4.1 EXPANSION OF LAB AUTOMATION AND RAPID DIAGNOSTIC PLATFORMS ACCELERATES INVESTMENT IN ADVANCED INSTRUMENTS 135
9.5 SOFTWARE 139
9.5.1 IMPLEMENTATION OF LAB INFORMATICS AND ANTIMICROBIAL STEWARDSHIP SOLUTIONS SUPPORTS SOFTWARE ADOPTION 139
10 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY 143
10.1 INTRODUCTION 144
10.2 BLOOD CULTURE (MICROBIOLOGY TESTING) 145
10.2.1 AS REGULATORY AND CLINICAL GOLD STANDARD, BLOOD CULTURE HOLDS LARGEST MARKET SHARE 145
10.3 IMMUNOASSAYS 148
10.3.1 EXPANDING ADOPTION OF HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS ASSESSMENT AND ANTIMICROBIAL STEWARDSHIP DRIVES MARKET GROWTH 148
10.4 MOLECULAR DIAGNOSTICS 151
10.4.1 PCR 157
10.4.1.1 Widespread hospital adoption of syndromic multiplex panels for rapid pathogen and resistance gene identification to propel market growth 157
10.4.2 MICROARRAYS 160
10.4.2.1 Stable utilization in established blood culture identification workflows supports moderate growth 160
10.4.3 FISH/PNA-FISH 164
10.4.3.1 Retention of rapid Gram stain-adjunct testing in cost-constrained laboratories sustains low-growth utilization amid progressive substitution 164
10.4.4 DNA SEQUENCING & NGS 168
10.4.4.1 Growing clinical interest in culture-independent broad-spectrum pathogen detection drives adoption, constrained by cost and reimbursement barriers 168
10.4.5 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES 171
10.5 FLOW CYTOMETRY 175
10.5.1 GROWING CLINICAL INTEREST IN CELLULAR HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS RISK ASSESSMENT SUPPORTS STEADY MARKET GROWTH 175
10.6 MASS SPECTROMETRY 179
10.6.1 RISING EMPHASIS ON RAPID DIAGNOSTICS, LAB AUTOMATION, AND ANTIMICROBIAL STEWARDSHIP PROPELS ADOPTION 179
10.7 CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS 183
10.7.1 WIDE UTILIZATION OF INFLAMMATORY BIOMARKERS AND RISING ADOPTION OF POC DIAGNOSTICS PROPEL MARKET GROWTH 183
11 SEPSIS DIAGNOSTICS MARKET, BY METHOD 188
11.1 INTRODUCTION 189
11.2 CONVENTIONAL DIAGNOSTICS 190
11.2.1 RELIANCE ON MANUAL MICROBIOLOGICAL AND BIOCHEMICAL WORKFLOWS IN RESOURCE-CONSTRAINED AND LOW-THROUGHPUT SETTINGS SUSTAINS DEMAND 190
11.3 AUTOMATED DIAGNOSTICS 193
11.3.1 GROWING INSTALLATION OF AUTOMATED PLATFORMS TO EXPEDITE TIME-TO-RESULT AND ADDRESS STAFFING SHORTAGES DRIVES SEGMENT GROWTH 193
12 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE 198
12.1 INTRODUCTION 199
12.2 BACTERIAL SEPSIS 200
12.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS 203
12.2.1.1 Rising prevalence of carbapenem-resistant and ESBL-producing organisms driving demand for resistance-marker testing 203
12.2.2 GRAM-POSITIVE BACTERIAL SEPSIS 207
12.2.2.1 Established diagnostic workflows for staphylococcal and enterococcal bloodstream infection sustain stable growth 207
12.3 FUNGAL SEPSIS 211
12.3.1 RISING INCIDENCE OF FUNGAL BLOODSTREAM INFECTIONS DRIVES DEMAND 211
12.4 OTHER PATHOGEN TYPES 214
13 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE 219
13.1 INTRODUCTION 220
13.2 LABORATORY TESTS 220
13.2.1 CENTRALIZATION OF BLOOD CULTURE, MOLECULAR, AND MASS SPECTROMETRY WORKFLOWS WITHIN ACCREDITED HOSPITAL LABORATORIES SUSTAINS THE DOMINANT SHARE 220
13.3 POC TESTS 223
13.3.1 EXPANDING NEAR-PATIENT LACTATE AND BIOMARKER TESTING TO MEET SEPSIS BUNDLE COMPLIANCE TIMELINES DRIVES GROWTH 223
14 SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE 227
14.1 INTRODUCTION 228
14.2 WHOLE BLOOD 228
14.2.1 EMERGENCE OF DIRECT-FROM-BLOOD MOLECULAR TESTING AND WIDESPREAD USAGE OF WHOLE BLOOD SPECIMENS DRIVE MARKET 228
14.3 SERUM 232
14.3.1 SUSTAINED RELIANCE ON SERUM AND PLASMA FOR BIOMARKER-BASED TRIAGE AND ANTIBIOTIC STEWARDSHIP MAINTAINS STABLE GROWTH 232
15 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY 236
15.1 INTRODUCTION 237
15.2 SINGLEPLEX 237
15.2.1 RECURRING VOLUME OF SINGLE-ANALYTE BIOMARKER AND CHEMISTRY TESTING SUSTAINS MARKET SHARE 237
15.3 MULTIPLEX 241
15.3.1 WIDESPREAD ADOPTION OF SYNDROMIC PANELS DELIVERING SIMULTANEOUS PATHOGEN AND RESISTANCE GENE IDENTIFICATION DRIVES GROWTH 241
16 SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY 245
16.1 INTRODUCTION 246
16.2 SEPSIS DIAGNOSIS 246
16.2.1 EXPANDING AVAILABILITY OF ASSAYS AND WIDESPREAD TESTING TO DRIVE MARKET 246
16.3 PATHOGEN IDENTIFICATION 249
16.3.1 ENTRENCHED CULTURE AND IDENTIFICATION WORKFLOWS SUSTAIN SUBSTANTIAL VOLUME 249
16.4 SEPSIS RISK STRATIFICATION 253
16.4.1 RISING DEPLOYMENT OF AUTOMATED SEVERITY SCORING AND CELLULAR HOST-RESPONSE MARKERS INTEGRATED WITH EARLY WARNING SYSTEMS DRIVES HIGH GROWTH 253
16.5 ANTIMICROBIAL STEWARDSHIP SUPPORT 256
16.5.1 INSTITUTIONAL REQUIREMENT FOR STEWARDSHIP AND ESCALATING BURDEN OF ANTIMICROBIAL RESISTANCE TO DRIVE MARKET 256
16.6 PROGNOSIS & OUTCOME PREDICTION 260
16.6.1 LIMITED UTILITY OF PROGNOSTIC INFORMATION CONTINUES TO HINDER DEDICATED ADOPTION 260
17 SEPSIS DIAGNOSTICS MARKET, BY END USER 264
17.1 INTRODUCTION 265
17.2 HOSPITALS & SPECIALTY CLINICS 266
17.2.1 INCREASING BURDEN OF SEPSIS AND GROWING ADOPTION OF RAPID DIAGNOSTIC WORKFLOWS IN ACUTE CARE SETTINGS TO DRIVE MARKET LEADERSHIP 266
17.3 PATHOLOGY & REFERENCE LABORATORIES 269
17.3.1 INCREASING OUTSOURCING OF SPECIALIZED MICROBIOLOGY AND MOLECULAR TESTING SUPPORTS STEADY MARKET GROWTH 269
17.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS 273
17.4.1 EXPANDING SEPSIS BIOMARKER RESEARCH AND DIAGNOSTIC INNOVATION CONTINUE TO SUPPORT LONG-TERM MARKET DEVELOPMENT 273
18 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION,
(NUMBER OF TESTS IN MILLIONS) 277
18.1 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION,
(NUMBER OF TESTS IN MILLIONS) 277
19 SEPSIS DIAGNOSTICS MARKET, BY REGION 278
19.1 INTRODUCTION 279
19.2 NORTH AMERICA 279
19.2.1 US 288
19.2.1.1 High burden of sepsis and early adoption of advanced diagnostic technologies drive market leadership 288
19.2.2 CANADA 294
19.2.2.1 Strong public healthcare infrastructure and expanding adoption of advanced microbiology technologies support market growth 294
19.3 EUROPE 299
19.3.1 GERMANY 305
19.3.1.1 Advanced clinical microbiology infrastructure and strong laboratory automation drive market leadership 305
19.3.2 UK 311
19.3.2.1 National sepsis initiatives and NHS investments continue to accelerate adoption of rapid diagnostics 311
19.3.3 FRANCE 316
19.3.3.1 Expansion of hospital microbiology networks and leadership of domestic diagnostic manufacturers drive growth 316
19.3.4 ITALY 321
19.3.4.1 Growing burden of HAIs supports adoption of advanced sepsis diagnostics 321
19.3.5 SWITZERLAND 327
19.3.5.1 Presence of global diagnostic manufacturers and strong healthcare investment support market growth 327
19.3.6 SPAIN 333
19.3.6.1 Increasing healthcare modernization and laboratory automation continue to strengthen market growth 333
19.3.7 REST OF EUROPE 338
19.4 ASIA PACIFIC 344
19.4.1 CHINA 351
19.4.1.1 Rapid healthcare modernization and expanding hospital laboratory infrastructure drive market growth 351
19.4.2 JAPAN 357
19.4.2.1 Advanced healthcare infrastructure and high adoption of innovative diagnostics support market expansion 357
19.4.3 INDIA 362
19.4.3.1 Expanding healthcare infrastructure and rising sepsis burden accelerate adoption of advanced diagnostics 362
19.4.4 SOUTH KOREA 367
19.4.4.1 Government investment in precision medicine and diagnostic innovation drives market expansion 367
19.4.5 AUSTRALIA 372
19.4.5.1 Strong clinical guidelines and high adoption of laboratory automation support market growth 372
19.4.6 REST OF ASIA PACIFIC 378
19.5 LATIN AMERICA 384
19.5.1 BRAZIL 390
19.5.1.1 Growing burden of infectious diseases and expansion of hospital laboratory infrastructure drive market growth 390
19.5.2 MEXICO 396
19.5.2.1 Healthcare modernization and expanding access to advanced diagnostics support market growth 396
19.5.3 REST OF LATIN AMERICA 401
19.6 MIDDLE EAST & AFRICA 407
19.6.1 GCC COUNTRIES 413
19.6.1.1 Healthcare modernization and government investments in advanced diagnostics drive regional growth 413
19.6.2 REST OF MIDDLE EAST & AFRICA 420
20 COMPETITIVE LANDSCAPE 426
20.1 INTRODUCTION 426
20.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 426
20.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN
SEPSIS DIAGNOSTICS MARKET 426
20.3 REVENUE ANALYSIS, 2023–2025 428
20.4 MARKET SHARE ANALYSIS, 2025 429
20.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 429
20.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 430
20.5.1 STARS 430
20.5.2 EMERGING LEADERS 430
20.5.3 PERVASIVE PLAYERS 431
20.5.4 PARTICIPANTS 431
20.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 432
20.5.5.1 Company footprint 432
20.5.5.2 Region footprint 433
20.5.5.3 Product footprint 434
20.5.5.4 Technology footprint 435
20.5.5.5 Pathogen type footprint 436
20.5.5.6 Test type footprint 436
20.5.5.7 Method footprint 437
20.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 438
20.6.1 PROGRESSIVE COMPANIES 438
20.6.2 RESPONSIVE COMPANIES 438
20.6.3 DYNAMIC COMPANIES 438
20.6.4 STARTING BLOCKS 438
20.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 439
20.6.5.1 Detailed list of key startups/SMEs 439
20.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 440
20.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 440
20.7 COMPANY VALUATION & FINANCIAL METRICS 441
20.7.1 FINANCIAL METRICS 441
20.7.2 COMPANY VALUATION 441
20.8 BRAND/PRODUCT COMPARISON 442
20.9 COMPETITIVE SCENARIO 443
20.9.1 PRODUCT LAUNCHES & APPROVALS 443
20.9.2 DEALS 444
20.9.3 OTHER DEVELOPMENTS 445
21 COMPANY PROFILES 446
21.1 KEY PLAYERS 446
21.1.1 BIOMÉRIEUX 446
21.1.1.1 Business overview 446
21.1.1.2 Products offered 447
21.1.1.3 Recent developments 448
21.1.1.3.1 Product launches & approvals 448
21.1.1.3.2 Deals 449
21.1.1.3.3 Other developments 449
21.1.1.4 MnM view 450
21.1.1.4.1 Key strengths 450
21.1.1.4.2 Strategic choices 450
21.1.1.4.3 Weaknesses & competitive threats 450
21.1.2 BECTON, DICKINSON AND COMPANY (BD) 451
21.1.2.1 Business overview 451
21.1.2.2 Products offered 452
21.1.2.3 Recent developments 453
21.1.2.3.1 Product launches & approvals 453
21.1.2.3.2 Deals 453
21.1.2.3.3 Other developments 454
21.1.2.4 MnM view 454
21.1.2.4.1 Key strengths 454
21.1.2.4.2 Strategic choices 454
21.1.2.4.3 Weaknesses and competitive threats 455
21.1.3 DANAHER 456
21.1.3.1 Business overview 456
21.1.3.2 Products offered 457
21.1.3.3 Recent developments 458
21.1.3.3.1 Deals 458
21.1.3.4 MnM view 458
21.1.3.4.1 Key strengths 458
21.1.3.4.2 Strategic choices 458
21.1.3.4.3 Weaknesses & competitive threats 459
21.1.4 DIASORIN S.P.A. 460
21.1.4.1 Business overview 460
21.1.4.2 Products offered 461
21.1.4.3 Recent developments 462
21.1.4.3.1 Product launches & approvals 462
21.1.4.4 MnM view 462
21.1.4.4.1 Key strengths 462
21.1.4.4.2 Strategic choices 463
21.1.4.4.3 Weaknesses & competitive threats 463
21.1.5 F. HOFFMANN-LA ROCHE LTD. 464
21.1.5.1 Business overview 464
21.1.5.2 Products offered 465
21.1.5.3 Recent developments 466
21.1.5.3.1 Product launches & approvals 466
21.1.5.4 MnM view 466
21.1.5.4.1 Key strengths 466
21.1.5.4.2 Strategic choices 466
21.1.5.4.3 Weaknesses & competitive threats 467
21.1.6 THERMO FISHER SCIENTIFIC INC. 468
21.1.6.1 Business overview 468
21.1.6.2 Products offered 469
21.1.7 BRUKER CORPORATION 470
21.1.7.1 Business overview 470
21.1.7.2 Products offered 471
21.1.7.3 Recent developments 472
21.1.7.3.1 Product launches & approvals 472
21.1.7.3.2 Other developments 472
21.1.8 ABBOTT 473
21.1.8.1 Business overview 473
21.1.8.2 Products offered 474
21.1.9 SYSMEX CORPORATION 475
21.1.9.1 Business overview 475
21.1.9.2 Products offered 476
21.1.9.3 Recent developments 477
21.1.9.3.1 Deals 477
21.1.10 SIEMENS HEALTHINEERS AG 478
21.1.10.1 Business overview 478
21.1.10.2 Products offered 479
21.1.11 QIAGEN 480
21.1.11.1 Business overview 480
21.1.11.2 Products offered 481
21.1.11.3 Recent developments 482
21.1.11.3.1 Product launches & approvals 482
21.1.12 SEEGENE INC. 483
21.1.12.1 Business overview 483
21.1.12.2 Products offered 484
21.1.12.3 Recent developments 484
21.1.12.3.1 Product launches & approvals 484
21.1.13 PHC HOLDINGS CORPORATION 485
21.1.13.1 Business overview 485
21.1.13.2 Products offered 487
21.1.14 QUIDELORTHO CORPORATION 488
21.1.14.1 Business overview 488
21.1.14.2 Products offered 490
21.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 491
21.1.15.1 Business overview 491
21.1.15.2 Products offered 492
21.2 OTHER PLAYERS 493
21.2.1 EKF DIAGNOSTICS HOLDINGS PLC 493
21.2.2 INFLAMMATIX, INC. 494
21.2.3 BODITECH MED INC 494
21.2.4 ALIFAX S.R.L. 495
21.2.5 ADVANDX (OPGEN) 495
21.2.6 FUJIREBIO 496
21.2.7 IMMUNEXPRESS 496
21.2.8 RESPONSE BIOMEDICAL CORPORATION 497
21.2.9 DEEPULL DIAGNOSTICS S.L. 497
21.2.10 SEKISUI DIAGNOSTICS 498
22 RESEARCH METHODOLOGY 499
22.1 RESEARCH DATA 499
22.2 SECONDARY DATA 500
22.2.1 LIST OF SECONDARY SOURCES 500
22.2.2 KEY DATA FROM SECONDARY SOURCES 501
22.2.3 PRIMARY DATA 501
22.2.3.1 List of primary sources 502
22.2.3.2 Key data from primary sources 503
22.2.3.3 Key industry insights 504
22.2.3.4 Breakdown of primary interviews 504
22.3 MARKET SIZE ESTIMATION 505
22.3.1 TOTAL MARKET SIZE: SEPSIS DIAGNOSTICS MARKET 505
22.3.2 BOTTOM-UP APPROACH 505
22.3.2.1 Approach 1: Revenue estimation of key players 505
22.3.2.2 Approach 2: Study of annual reports and investor presentations 506
22.3.2.3 Approach 3: Primary interviews 506
22.3.2.4 Growth forecast 506
22.3.2.5 CAGR projections 507
22.3.3 TOP-DOWN APPROACH 508
22.4 DATA TRIANGULATION 508
22.5 RESEARCH ASSUMPTIONS 509
22.5.1 STUDY ASSUMPTIONS 509
22.5.2 PARAMETRIC ASSUMPTIONS 510
22.5.3 GROWTH RATE ASSUMPTIONS 510
22.6 RESEARCH LIMITATIONS 511
22.7 RISK ASSESSMENT 511
23 APPENDIX 512
23.1 DISCUSSION GUIDE 512
23.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 517
23.3 CUSTOMIZATION OPTIONS 519
23.4 RELATED REPORTS 519
23.5 AUTHOR DETAILS 520
圖表清單 List of Tables & Figures
TABLE 1 SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 76
TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 78
TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS 79
TABLE 4 EUROPE: MACROECONOMIC INDICATORS 79
TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS 80
TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS 80
TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 80
TABLE 8 AVERAGE SELLING PRICE TREND OF SEPSIS DIAGNOSTICS PRODUCTS,
BY KEY PLAYER, 2024–2026 (USD) 90
TABLE 9 AVERAGE SELLING PRICE TREND OF SEPSIS DIAGNOSTICS PRODUCTS,
BY REGION, 2024–2026 (USD) 91
TABLE 10 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 92
TABLE 11 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 93
TABLE 12 SEPSIS DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS,
2026–2027 93
TABLE 13 US-ADJUSTED RECIPROCAL TARIFF RATES 96
TABLE 14 KEY PATENTS IN SEPSIS DIAGNOSTICS MARKET, 2022–2026 104
TABLE 15 KEY COMPANIES IMPLEMENTING AI IN COMPANION DIAGNOSTICS MARKET 108
TABLE 16 CLASSIFICATION OF IVD DEVICES IN EUROPE 110
TABLE 17 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 112
TABLE 18 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA 113
TABLE 19 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 115
TABLE 20 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 115
TABLE 21 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 115
TABLE 22 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 116
TABLE 23 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 116
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 120
TABLE 25 KEY BUYING CRITERIA, BY PRODUCT 121
TABLE 26 ADOPTION BARRIERS & INTERNAL CHALLENGES 122
TABLE 27 SEPSIS DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 124
TABLE 28 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 127
TABLE 29 KEY BLOOD CULTURE MEDIA, BY COMPANY 128
TABLE 30 SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY REGION,
2024–2031 (USD MILLION) 128
TABLE 31 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 32 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 33 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 34 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 35 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 36 KEY ASSAYS & REAGENT KITS, BY COMPANY 132
TABLE 37 SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY REGION,
2024–2031 (USD MILLION) 132
TABLE 38 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 39 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS,
BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 40 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 41 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 42 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 43 KEY INSTRUMENTS/SYSTEMS, BY COMPANY 136
TABLE 44 SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,
2024–2031 (USD MILLION) 136
TABLE 45 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 46 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY,
2024–2031 (USD MILLION) 137
TABLE 47 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 48 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 49 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 50 KEY SOFTWARE, BY COMPANY 139
TABLE 51 SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY REGION,
2024–2031 (USD MILLION) 140
TABLE 52 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 53 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY,
2024–2031 (USD MILLION) 141
TABLE 54 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 55 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 56 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE,
BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 57 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 144
TABLE 58 SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY REGION, 2024–2031 (USD MILLION) 145
TABLE 59 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 60 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 61 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 62 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 63 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 64 SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION,
2024–2031 (USD MILLION) 149
TABLE 65 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 66 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 67 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 68 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 69 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 70 SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 153
TABLE 71 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 72 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 73 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS
BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 74 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 75 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 76 SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE,
2024–2031 (USD MILLION) 156
TABLE 77 SEPSIS DIAGNOSTICS MARKET FOR PCR, BY REGION, 2024–2031 (USD MILLION) 158
TABLE 78 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY,
2024–2031 (USD MILLION) 158
TABLE 79 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 80 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 81 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 82 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 83 SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY REGION,
2024–2031 (USD MILLION) 161
TABLE 84 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 85 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY,
2024–2031 (USD MILLION) 162
TABLE 86 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 87 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 88 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 89 SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY REGION,
2024–2031 (USD MILLION) 165
TABLE 90 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH,
BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 91 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY,
2024–2031 (USD MILLION) 166
TABLE 92 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 93 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 94 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 95 SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION,
2024–2031 (USD MILLION) 169
TABLE 96 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 97 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS,
BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 98 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS,
BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 99 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS,
BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 100 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 101 SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 173
TABLE 102 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 103 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 104 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 105 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 106 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 107 SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY REGION,
2024–2031 (USD MILLION) 177
TABLE 108 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 109 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 110 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 111 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 112 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 113 SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY REGION,
2024–2031 (USD MILLION) 180
TABLE 114 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 115 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 116 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 117 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 118 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 119 SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY REGION, 2024–2031 (USD MILLION) 185
TABLE 120 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 121 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 122 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 123 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 124 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 125 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 189
TABLE 126 CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY REGION,
2024–2031 (USD MILLION) 191
TABLE 127 NORTH AMERICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 128 EUROPE: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 192
TABLE 129 ASIA PACIFIC: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 130 LATIN AMERICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 131 MIDDLE EAST & AFRICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 132 AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY REGION,
2024–2031 (USD MILLION) 194
TABLE 133 NORTH AMERICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 134 EUROPE: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 195
TABLE 135 ASIA PACIFIC: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 196
TABLE 136 LATIN AMERICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 196
TABLE 137 MIDDLE EAST & AFRICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 138 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION) 199
TABLE 139 BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION,
2024–2031 (USD MILLION) 200
TABLE 140 NORTH AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 201
TABLE 141 EUROPE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 201
TABLE 142 ASIA PACIFIC: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 202
TABLE 143 LATIN AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 202
TABLE 144 MIDDLE EAST & AFRICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 145 BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 146 GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION,
2024–2031 (USD MILLION) 204
TABLE 147 NORTH AMERICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 148 EUROPE: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 149 ASIA PACIFIC: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 150 LATIN AMERICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 151 MIDDLE EAST & AFRICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 152 GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION,
2024–2031 (USD MILLION) 208
TABLE 153 NORTH AMERICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 154 EUROPE: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 155 ASIA PACIFIC: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 156 LATIN AMERICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 157 MIDDLE EAST & AFRICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 158 FUNGAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 212
TABLE 159 NORTH AMERICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 212
TABLE 160 EUROPE: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 213
TABLE 161 ASIA PACIFIC: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 213
TABLE 162 LATIN AMERICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 214
TABLE 163 MIDDLE EAST & AFRICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 164 SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY REGION,
2024–2031 (USD MILLION) 215
TABLE 165 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 166 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES,
BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 167 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES,
BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 168 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES,
BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 169 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 170 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 220
TABLE 171 SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION,
2024–2031 (USD MILLION) 221
TABLE 172 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 173 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 174 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 175 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 176 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 177 SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY REGION,
2024–2031 (USD MILLION) 224
TABLE 178 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 179 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY,
2024–2031 (USD MILLION) 225
TABLE 180 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 181 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 182 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS,
BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 183 SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 228
TABLE 184 SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY REGION,
2024–2031 (USD MILLION) 229
TABLE 185 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD,
BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 186 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 187 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 188 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 189 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD,
BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 190 SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY REGION,
2024–2031 (USD MILLION) 233
TABLE 191 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 192 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY,
2024–2031 (USD MILLION) 234
TABLE 193 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY,
2024–2031 (USD MILLION) 234
TABLE 194 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY,
2024–2031 (USD MILLION) 235
TABLE 195 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM,
BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 196 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 237
TABLE 197 SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY REGION,
2024–2031 (USD MILLION) 238
TABLE 198 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 199 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY,
2024–2031 (USD MILLION) 239
TABLE 200 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 201 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 202 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX,
BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 203 SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY REGION,
2024–2031 (USD MILLION) 242
TABLE 204 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 205 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY,
2024–2031 (USD MILLION) 243
TABLE 206 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 207 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX,
BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 208 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX,
BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 209 SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 246
TABLE 210 SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY REGION,
2024–2031 (USD MILLION) 247
TABLE 211 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS,
BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 212 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 213 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS,
BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 214 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS,
BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 215 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 216 SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY REGION, 2024–2031 (USD MILLION) 250
TABLE 217 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 218 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION,
BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 219 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION,
BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 220 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 221 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 222 SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY REGION, 2024–2031 (USD MILLION) 254
TABLE 223 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 224 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION,
BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 225 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 226 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 227 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 228 SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT,
BY REGION, 2024–2031 (USD MILLION) 257
TABLE 229 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION) 258
TABLE 230 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION) 258
TABLE 231 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 232 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 233 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 234 SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION,
BY REGION, 2024–2031 (USD MILLION) 261
TABLE 235 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 236 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 237 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 238 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 239 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 240 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 265
TABLE 241 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION) 267
TABLE 242 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 243 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 244 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 245 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 246 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 247 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 270
TABLE 248 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 249 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 250 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 251 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 252 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 273
TABLE 253 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY REGION, 2024–2031 (USD MILLION) 274
TABLE 254 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 255 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 256 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 257 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 258 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY,
2024–2031 (USD MILLION) 276
TABLE 259 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION,
2024–2031 (MILLION TESTS) 277
TABLE 260 SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 279
TABLE 261 NORTH AMERICA: MACROECONOMIC INDICATORS 281
TABLE 262 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 282
TABLE 263 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 282
TABLE 264 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 283
TABLE 265 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 266 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 284
TABLE 267 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 284
TABLE 268 NORTH AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 285
TABLE 269 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 285
TABLE 270 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 286
TABLE 271 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 286
TABLE 272 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 287
TABLE 273 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 287
TABLE 274 US: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 289
TABLE 275 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 289
TABLE 276 US: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 277 US: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 290
TABLE 278 US: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 291
TABLE 279 US: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 291
TABLE 280 US: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 292
TABLE 281 US: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 292
TABLE 282 US: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 292
TABLE 283 US: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 293
TABLE 284 US: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 293
TABLE 285 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 294
TABLE 286 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 295
TABLE 287 CANADA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 295
TABLE 288 CANADA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 296
TABLE 289 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 296
TABLE 290 CANADA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 297
TABLE 291 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 297
TABLE 292 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 297
TABLE 293 CANADA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 298
TABLE 294 CANADA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 298
TABLE 295 CANADA: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 299
TABLE 296 EUROPE: MACROECONOMIC INDICATORS 299
TABLE 297 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 300
TABLE 298 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 300
TABLE 299 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 301
TABLE 300 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 301
TABLE 301 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 302
TABLE 302 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 302
TABLE 303 EUROPE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 303
TABLE 304 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 303
TABLE 305 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 303
TABLE 306 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 304
TABLE 307 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 304
TABLE 308 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 305
TABLE 309 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 306
TABLE 310 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 306
TABLE 311 GERMANY: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 307
TABLE 312 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 307
TABLE 313 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 308
TABLE 314 GERMANY: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 308
TABLE 315 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 309
TABLE 316 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 309
TABLE 317 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 309
TABLE 318 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 310
TABLE 319 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 310
TABLE 320 UK: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 311
TABLE 321 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 312
TABLE 322 UK: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 312
TABLE 323 UK: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 313
TABLE 324 UK: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 313
TABLE 325 UK: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 313
TABLE 326 UK: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 314
TABLE 327 UK: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 314
TABLE 328 UK: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 314
TABLE 329 UK: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 315
TABLE 330 UK: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 315
TABLE 331 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 316
TABLE 332 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 317
TABLE 333 FRANCE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 334 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 318
TABLE 335 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 318
TABLE 336 FRANCE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 319
TABLE 337 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 319
TABLE 338 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 319
TABLE 339 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 320
TABLE 340 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 320
TABLE 341 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 321
TABLE 342 ITALY: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 322
TABLE 343 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 322
TABLE 344 ITALY: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 323
TABLE 345 ITALY: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 323
TABLE 346 ITALY: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 324
TABLE 347 ITALY: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 324
TABLE 348 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 324
TABLE 349 ITALY: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 325
TABLE 350 ITALY: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 325
TABLE 351 ITALY: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 326
TABLE 352 ITALY: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 326
TABLE 353 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 327
TABLE 354 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 328
TABLE 355 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 328
TABLE 356 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 329
TABLE 357 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 329
TABLE 358 SWITZERLAND: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 330
TABLE 359 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 330
TABLE 360 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 331
TABLE 361 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 331
TABLE 362 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 332
TABLE 363 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 332
TABLE 364 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 333
TABLE 365 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 334
TABLE 366 SPAIN: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 334
TABLE 367 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 335
TABLE 368 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 335
TABLE 369 SPAIN: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 336
TABLE 370 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 336
TABLE 371 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 336
TABLE 372 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 337
TABLE 373 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 337
TABLE 374 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 338
TABLE 375 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 339
TABLE 376 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 339
TABLE 377 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 340
TABLE 378 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 340
TABLE 379 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 341
TABLE 380 REST OF EUROPE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 341
TABLE 381 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 342
TABLE 382 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 342
TABLE 383 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 343
TABLE 384 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 343
TABLE 385 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 344
TABLE 386 ASIA PACIFIC: MACROECONOMIC INDICATORS 345
TABLE 387 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 346
TABLE 388 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 346
TABLE 389 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 347
TABLE 390 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 347
TABLE 391 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 348
TABLE 392 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 348
TABLE 393 ASIA PACIFIC: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 349
TABLE 394 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 349
TABLE 395 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 349
TABLE 396 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 350
TABLE 397 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 350
TABLE 398 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 351
TABLE 399 CHINA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 352
TABLE 400 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 352
TABLE 401 CHINA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 353
TABLE 402 CHINA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 353
TABLE 403 CHINA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 354
TABLE 404 CHINA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 354
TABLE 405 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 354
TABLE 406 CHINA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 355
TABLE 407 CHINA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 355
TABLE 408 CHINA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 356
TABLE 409 CHINA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 356
TABLE 410 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 357
TABLE 411 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 358
TABLE 412 JAPAN: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 358
TABLE 413 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 359
TABLE 414 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 359
TABLE 415 JAPAN: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 359
TABLE 416 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 360
TABLE 417 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 360
TABLE 418 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 360
TABLE 419 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 361
TABLE 420 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 361
TABLE 421 INDIA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 362
TABLE 422 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 363
TABLE 423 INDIA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 363
TABLE 424 INDIA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 364
TABLE 425 INDIA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 364
TABLE 426 INDIA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 364
TABLE 427 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 365
TABLE 428 INDIA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 365
TABLE 429 INDIA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 365
TABLE 430 INDIA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 366
TABLE 431 INDIA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 366
TABLE 432 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 367
TABLE 433 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 368
TABLE 434 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 368
TABLE 435 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 369
TABLE 436 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 369
TABLE 437 SOUTH KOREA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 370
TABLE 438 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 370
TABLE 439 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 370
TABLE 440 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 371
TABLE 441 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 371
TABLE 442 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 372
TABLE 443 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 373
TABLE 444 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 373
TABLE 445 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 374
TABLE 446 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 374
TABLE 447 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 375
TABLE 448 AUSTRALIA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 375
TABLE 449 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 376
TABLE 450 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 376
TABLE 451 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 376
TABLE 452 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 377
TABLE 453 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 377
TABLE 454 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 378
TABLE 455 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 379
TABLE 456 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 379
TABLE 457 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 380
TABLE 458 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION) 380
TABLE 459 REST OF ASIA PACIFIC: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 381
TABLE 460 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 381
TABLE 461 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 382
TABLE 462 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 382
TABLE 463 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 383
TABLE 464 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 383
TABLE 465 LATIN AMERICA: MACROECONOMIC INDICATORS 384
TABLE 466 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 384
TABLE 467 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 385
TABLE 468 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 385
TABLE 469 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 386
TABLE 470 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 386
TABLE 471 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 387
TABLE 472 LATIN AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 387
TABLE 473 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 388
TABLE 474 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 388
TABLE 475 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 388
TABLE 476 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 389
TABLE 477 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 389
TABLE 478 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 391
TABLE 479 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 391
TABLE 480 BRAZIL: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 392
TABLE 481 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 392
TABLE 482 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 393
TABLE 483 BRAZIL: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 393
TABLE 484 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 393
TABLE 485 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 394
TABLE 486 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 394
TABLE 487 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 395
TABLE 488 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 395
TABLE 489 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 396
TABLE 490 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 397
TABLE 491 MEXICO: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 397
TABLE 492 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 398
TABLE 493 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 398
TABLE 494 MEXICO: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 399
TABLE 495 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 399
TABLE 496 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 399
TABLE 497 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 400
TABLE 498 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 400
TABLE 499 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 401
TABLE 500 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 402
TABLE 501 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 402
TABLE 502 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 403
TABLE 503 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 403
TABLE 504 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION) 404
TABLE 505 REST OF LATIN AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 506 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 405
TABLE 507 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 405
TABLE 508 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 405
TABLE 509 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 406
TABLE 510 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 406
TABLE 511 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 407
TABLE 512 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 408
TABLE 513 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 408
TABLE 514 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 409
TABLE 515 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 409
TABLE 516 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION) 410
TABLE 517 MIDDLE EAST & AFRICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 518 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 411
TABLE 519 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 411
TABLE 520 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 412
TABLE 521 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 412
TABLE 522 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 413
TABLE 523 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 414
TABLE 524 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 415
TABLE 525 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 526 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 416
TABLE 527 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2024–2031 (USD MILLION) 416
TABLE 528 GCC COUNTRIES: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 417
TABLE 529 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2024–2031 (USD MILLION) 417
TABLE 530 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY,
2024–2031 (USD MILLION) 418
TABLE 531 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 418
TABLE 532 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 419
TABLE 533 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 419
TABLE 534 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 420
TABLE 535 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 421
TABLE 536 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 421
TABLE 537 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 422
TABLE 538 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION) 422
TABLE 539 REST OF MIDDLE EAST & AFRICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 540 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 423
TABLE 541 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION) 424
TABLE 542 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 424
TABLE 543 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION) 425
TABLE 544 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 425
TABLE 545 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN SEPSIS DIAGNOSTICS MARKET, JANUARY 2023–JUNE 2026 426
TABLE 546 SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION 429
TABLE 547 SEPSIS DIAGNOSTICS MARKET: REGION FOOTPRINT 433
TABLE 548 SEPSIS DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 434
TABLE 549 SEPSIS DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 435
TABLE 550 SEPSIS DIAGNOSTICS MARKET: PATHOGEN TYPE FOOTPRINT 436
TABLE 551 SEPSIS DIAGNOSTICS MARKET: TEST TYPE FOOTPRINT 436
TABLE 552 SEPSIS DIAGNOSTICS MARKET: METHOD FOOTPRINT 437
TABLE 553 SEPSIS DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 439
TABLE 554 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 440
TABLE 555 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 440
TABLE 556 SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–JUNE 2026 443
TABLE 557 SEPSIS DIAGNOSTICS MARKET: DEALS, JANUARY 2023–JUNE 2026 444
TABLE 558 SEPSIS DIAGNOSTICS MARKET: OTHER DEVELOPMENTS,
JANUARY 2023–JUNE 2026 445
TABLE 559 BIOMÉRIEUX: COMPANY OVERVIEW 446
TABLE 560 BIOMÉRIEUX: PRODUCTS OFFERED 447
TABLE 561 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 448
TABLE 562 BIOMÉRIEUX: DEALS, JANUARY 2023–JUNE 2026 449
TABLE 563 BIOMÉRIEUX: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 449
TABLE 564 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 451
TABLE 565 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 452
TABLE 566 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 453
TABLE 567 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2023–JUNE 2026 453
TABLE 568 BECTON, DICKINSON AND COMPANY (BD): OTHER DEVELOPMENTS,
JANUARY 2023–JUNE 2026 454
TABLE 569 DANAHER: COMPANY OVERVIEW 456
TABLE 570 DANAHER: PRODUCTS OFFERED 457
TABLE 571 DANAHER: DEALS, JANUARY 2023–JUNE 2026 458
TABLE 572 DIASORIN S.P.A.: COMPANY OVERVIEW 460
TABLE 573 DIASORIN S.P.A.: PRODUCTS OFFERED 461
TABLE 574 DIASORIN S.P.A: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 462
TABLE 575 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 464
TABLE 576 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 465
TABLE 577 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–JUNE 2026 466
TABLE 578 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 468
TABLE 579 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 469
TABLE 580 BRUKER CORPORATION: COMPANY OVERVIEW 470
TABLE 581 BRUKER CORPORATION: PRODUCTS OFFERED 471
TABLE 582 BRUKER CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–JUNE 2026 472
TABLE 583 BRUKER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 472
TABLE 584 ABBOTT: COMPANY OVERVIEW 473
TABLE 585 ABBOTT: PRODUCTS OFFERED 474
TABLE 586 SYSMEX CORPORATION: COMPANY OVERVIEW 475
TABLE 587 SYSMEX CORPORATION: PRODUCTS OFFERED 476
TABLE 588 SYSMEX CORPORATION: DEALS, JANUARY 2023–JUNE 2026 477
TABLE 589 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 478
TABLE 590 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 479
TABLE 591 QIAGEN: COMPANY OVERVIEW 480
TABLE 592 QIAGEN: PRODUCTS OFFERED 481
TABLE 593 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 482
TABLE 594 SEEGENE INC.: COMPANY OVERVIEW 483
TABLE 595 SEEGENE INC.: PRODUCTS OFFERED 484
TABLE 596 SEEGENE INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 484
TABLE 597 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW 485
TABLE 598 PHC HOLDINGS CORPORATION: PRODUCTS OFFERED 487
TABLE 599 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 489
TABLE 600 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 490
TABLE 601 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 491
TABLE 602 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 492
TABLE 603 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW 493
TABLE 604 INFLAMMATIX, INC.: COMPANY OVERVIEW 494
TABLE 605 BODITECH MED INC.: COMPANY OVERVIEW 494
TABLE 606 ALIFAX S.R.L.: COMPANY OVERVIEW 495
TABLE 607 ADVANDX (OPGEN): COMPANY OVERVIEW 495
TABLE 608 FUJIREBIO: COMPANY OVERVIEW 496
TABLE 609 IMMUNEXPRESS: COMPANY OVERVIEW 496
TABLE 610 RESPONSE BIOMEDICAL CORPORATION: COMPANY OVERVIEW 497
TABLE 611 DEEPULL DIAGNOSTICS S.L.: COMPANY OVERVIEW 497
TABLE 612 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW 498
TABLE 613 SEPSIS DIAGNOSTICS MARKET: RISK ASSESSMENT 511
FIGURE 1 SEPSIS DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE 47
FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 51
FIGURE 3 GLOBAL SEPSIS DIAGNOSTICS MARKET, 2024–2031 52
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN SEPSIS
DIAGNOSTICS MARKET, 2023–2025 52
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF SEPSIS DIAGNOSTICS MARKET 53
FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN
SEPSIS DIAGNOSTICS MARKET, 2025 54
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 55
FIGURE 8 INCREASING ADOPTION OF TARGETED THERAPIES TO DRIVE MARKET 56
FIGURE 9 ASSAYS & REAGENT KITS SEGMENT TO DOMINATE MARKET
DURING FORECAST PERIOD 57
FIGURE 10 BLOOD CULTURE (MICROBIOLOGY TESTING) SEGMENT TO
LEAD MARKET DURING FORECAST PERIOD 57
FIGURE 11 AUTOMATED DIAGNOSTICS SEGMENT TO LEAD MARKET
DURING FORECAST PERIOD 58
FIGURE 12 BACTERIAL SEPSIS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 58
FIGURE 13 LABORATORY TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 59
FIGURE 14 WHOLE BLOOD SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 59
FIGURE 15 SINGLEPLEX SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 60
FIGURE 16 SEPSIS DIAGNOSIS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 60
FIGURE 17 HOSPITALS & SPECIALTY CLINICS SEGMENT TO LEAD MARKET
DURING FORECAST PERIOD 61
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 61
FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 63
FIGURE 20 SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 75
FIGURE 21 SEPSIS DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 83
FIGURE 22 SEPSIS DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 85
FIGURE 23 SEPSIS DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 88
FIGURE 24 SEPSIS DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS
IMPACTING CUSTOMERS’ BUSINESSES 95
FIGURE 25 DEALS & FUNDING ACTIVITIES IN SEPSIS DIAGNOSTICS MARKET 95
FIGURE 26 PATENT ANALYSIS FOR SEPSIS DIAGNOSTICS MARKET, JANUARY 2016–DECEMBER 2025 103
FIGURE 27 MARKET POTENTIAL OF AI IN SEPSIS DIAGNOSTICS MARKET 107
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 120
FIGURE 29 KEY BUYING CRITERIA, BY PRODUCT 121
FIGURE 30 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT 281
FIGURE 31 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT 345
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN SEPSIS DIAGNOSTICS MARKET,
2023–2025 (USD MILLION) 428
FIGURE 33 SEPSIS DIAGNOSTICS MARKET SHARE ANALYSIS, 2025 (GLOBAL) 429
FIGURE 34 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 431
FIGURE 35 SEPSIS DIAGNOSTICS MARKET: COMPANY FOOTPRINT 432
FIGURE 36 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 439
FIGURE 37 EV/EBITDA OF KEY VENDORS 441
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 441
FIGURE 39 SEPSIS DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
FOR SEPSIS DIAGNOSTICS 442
FIGURE 40 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 447
FIGURE 41 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025) 452
FIGURE 42 DANAHER: COMPANY SNAPSHOT (2025) 457
FIGURE 43 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 461
FIGURE 44 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 465
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 469
FIGURE 46 BRUKER CORPORATION: COMPANY SNAPSHOT (2025) 471
FIGURE 47 ABBOTT: COMPANY SNAPSHOT (2025) 474
FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025) 476
FIGURE 49 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 479
FIGURE 50 QIAGEN: COMPANY SNAPSHOT (2025) 481
FIGURE 51 SEEGENE INC.: COMPANY SNAPSHOT (2025) 483
FIGURE 52 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2025) 486
FIGURE 53 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025) 489
FIGURE 54 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.:
COMPANY SNAPSHOT (2025) 492
FIGURE 55 RESEARCH DESIGN 499
FIGURE 56 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 504
FIGURE 57 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030): IMPACT ON MARKET GROWTH AND CAGR 507
FIGURE 58 TOP-DOWN APPROACH 508
FIGURE 59 DATA TRIANGULATION 509
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們